AU749169B2 - A method for preventing the onset of asthma - Google Patents

A method for preventing the onset of asthma Download PDF

Info

Publication number
AU749169B2
AU749169B2 AU57346/99A AU5734699A AU749169B2 AU 749169 B2 AU749169 B2 AU 749169B2 AU 57346/99 A AU57346/99 A AU 57346/99A AU 5734699 A AU5734699 A AU 5734699A AU 749169 B2 AU749169 B2 AU 749169B2
Authority
AU
Australia
Prior art keywords
patient
asthma
cetirizine
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU57346/99A
Other languages
English (en)
Other versions
AU5734699A (en
Inventor
Johan De Clercq
Marc De Longueville
Luc Uylenbroeck
Anne Wilmes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Farchim SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26792214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU749169(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Publication of AU5734699A publication Critical patent/AU5734699A/en
Application granted granted Critical
Publication of AU749169B2 publication Critical patent/AU749169B2/en
Assigned to UCB FARCHIM SA reassignment UCB FARCHIM SA Alteration of Name(s) in Register under S187 Assignors: UCB
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AU57346/99A 1998-08-18 1999-08-14 A method for preventing the onset of asthma Ceased AU749169B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9692998P 1998-08-18 1998-08-18
US60/096929 1998-08-18
US9745598P 1998-08-21 1998-08-21
US60/097455 1998-08-21
PCT/EP1999/005969 WO2000010544A2 (en) 1998-08-18 1999-08-14 A method for preventing the onset of asthma

Publications (2)

Publication Number Publication Date
AU5734699A AU5734699A (en) 2000-03-14
AU749169B2 true AU749169B2 (en) 2002-06-20

Family

ID=26792214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57346/99A Ceased AU749169B2 (en) 1998-08-18 1999-08-14 A method for preventing the onset of asthma

Country Status (16)

Country Link
EP (1) EP1109557B1 (enExample)
JP (1) JP3878416B2 (enExample)
AR (1) AR020167A1 (enExample)
AT (1) ATE228366T1 (enExample)
AU (1) AU749169B2 (enExample)
CA (1) CA2340920C (enExample)
DE (1) DE69904206T2 (enExample)
ES (1) ES2188232T3 (enExample)
HN (1) HN1999000140A (enExample)
MA (1) MA26676A1 (enExample)
MY (1) MY124089A (enExample)
PA (1) PA8480401A1 (enExample)
SA (1) SA99200492B1 (enExample)
TN (1) TNSN99158A1 (enExample)
TW (1) TW581675B (enExample)
WO (1) WO2000010544A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221854A1 (en) * 2000-12-15 2002-06-24 U C B, S.A. Use of cetirizine or efletirizine for preventing urticaria
WO2005077371A1 (en) * 2004-02-12 2005-08-25 Ucb Farchim Sa Use of levocetirizine for the preparation of a drug
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIJKMAN ET AL, CLIN.EXP. ALLERGY, VOL.20, 1990 P 4383-490 *
SCHWARTZ, PHARMAZIE, VOL.20, NO. 138, 20 MAY 93, P 34 *
WARNER, PEDIATRIC ALLERGY & IMMUNOLOGY 97, VOL.8 P 46-48 *

Also Published As

Publication number Publication date
AR020167A1 (es) 2002-04-10
HN1999000140A (es) 2001-07-31
DE69904206T2 (de) 2003-07-17
PA8480401A1 (es) 2000-09-29
DE69904206D1 (de) 2003-01-09
AU5734699A (en) 2000-03-14
CA2340920C (en) 2007-10-16
WO2000010544A2 (en) 2000-03-02
ES2188232T3 (es) 2003-06-16
TW581675B (en) 2004-04-01
CA2340920A1 (en) 2000-03-02
MY124089A (en) 2006-06-30
EP1109557B1 (en) 2002-11-27
WO2000010544A3 (en) 2000-05-18
ATE228366T1 (de) 2002-12-15
JP3878416B2 (ja) 2007-02-07
MA26676A1 (fr) 2004-12-20
SA99200492B1 (ar) 2006-06-04
JP2002523362A (ja) 2002-07-30
EP1109557A2 (en) 2001-06-27
TNSN99158A1 (ar) 2005-11-10

Similar Documents

Publication Publication Date Title
JP7555346B2 (ja) 疾患の治療のためのロイシン、アセチルロイシン、及び関連類似体
Tanz et al. Treating tinea capitis: Should ketoconazole replace griseofulvin?
JP2014058542A (ja) アルコール摂取症状を軽減するための方法
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
CN114504578A (zh) 治疗、预防由病毒感染引起的相关疾病的药物及其用途
CA2340920C (en) A method for preventing the onset of asthma
US6432961B1 (en) Method for preventing the onset of asthma
EP3131545B1 (en) Use of enoximone in the treatment of atopic immune-related disorders, in pharmaceutical compositions as well as in pharmaceutical preparations
JP4384435B2 (ja) くしゃみ抑制組成物
Clark et al. Combination of aminophylline (Phyllocontin Continus tablets) and salbutamol in the management of chronic obstructive airways disease.
EP1569650B1 (en) Use of levocetirizine for the treatment of persistent allergic rhinitis
WO2002047689A2 (en) Use of cetirizine or efletirizine for preventing urticaria
WO2003020274A1 (en) Treatment of atopic dermatitis
JPWO2004039408A1 (ja) 医薬組成物
KORSANTIA et al. PEMPHIGUS VULGARIS, CURRENT STATUS AND PROSPECTS
Agent PrMINT-OLOPATADINE 0.2%
Spector Ocular, nasal and oral cromolyn sodium in the management of non-asthmatic allergic problems
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
JPH0623111B2 (ja) 抗白内障剤
WO2004105760A1 (en) Use of efletirizine for treating persistent allergic rhinitis
Emerson RECOVERY FROM GLYCOSURIA FOLLOWING CHOLECYSTECTOMY
JPH11255641A (ja) 医薬組成物
MXPA99003936A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO READ UCB

FGA Letters patent sealed or granted (standard patent)